<DOC>
	<DOCNO>NCT00758160</DOCNO>
	<brief_summary>The purpose study evaluate whether familial relationship psychological status participant caregiver well Attention Deficit Hyperactivity Disorder ( ADHD ) symptoms participant improved switch Immediate-release Methylphenidate ( IR-MPH ) Osmotic Release Oral Delivery System Methylphenidate ( OROS-MPH ) .</brief_summary>
	<brief_title>The Impact Osmotic Release Oral Delivery System Methylphenidate ( OROS MPH ) Upon Family Children Adolescents With Attention Deficit Hyperactivity Disorder ( ADHD )</brief_title>
	<detailed_description>This prospective ( study follow participant forward time ) , single-arm , open-label ( people know identity intervention ) , 8-week , multi-centric ( conducted 1 center ) study . OROS-MPH administer orally 2 month dose 18 , 36 , 54 milligram ( mg ) replace IR-MPH . Clinicians adjust dose participant accord participant 's clinical response and/or side effect . During study period , participant assess Week 2 , 4 , 8 . Efficacy evaluate primarily base change baseline Chinese version 26-item Swanson , Nolan Pelham-Fourth Edition ( SNAP-IV ) rating scale assess parent Chinese Health Questionnaire ( CHQ ) . Safety monitor throughout study .</detailed_description>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<criteria>Participants diagnose Attention Deficit Hyperactivity Disorder ( ADHD ) accord Diagnostic Statistical Manual Mental Disorders , Fourth Edition ( DSMIV ) Participants treat Immediaterelease methyphenidate ( IRMPH ) least 4 week enrollment , previous treatment consider unsatisfactory due 1 follow reason : lack effectiveness , lack tolerability safety , lack compliance , and/or reason Participants able comply study visit schedule whose parents/caregiver community school teacher willing able complete protocolspecified assessment Participants still school Participants treat great equal 10 milligram ( mg ) IRMPH daily enrollment Participants understand follow instruction give study Participants serious unstable medical illness Participants clinically significant gastrointestinal problem , include narrow gastrointestinal tract Participants glaucoma ( increased pressure inside eye cause visual problem ) , ongoing seizure disorder , psychotic disorder Participants hypersensitive methylphenidate Participants coexist medical condition take concomitant medication likely interfere safe administration methylphenidate</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Attention Deficit Disorder With Hyperactivity</keyword>
	<keyword>Methylphenidate</keyword>
	<keyword>Concerta</keyword>
</DOC>